Increasing lipid yield in *Yarrowia lipolytica* through phosphoketolase and phosphotransacetylase expression in a phosphofructokinase deletion strain

Annapurna Kamineni1*, Andrew L. Consiglio1, Kyle MacEwen1, Shuyan Chen1, Gamuchirai Chifamba1, A. Joe Shaw2 and Vasiliki Tsakraklides1

**Abstract**

**Background:** Lipids are important precursors in the biofuel and oleochemical industries. *Yarrowia lipolytica* is among the most extensively studied oleaginous microorganisms and has been a focus of metabolic engineering to improve lipid production. Yield improvement, through rewiring of the central carbon metabolism of *Y. lipolytica* from glucose to the lipid precursor acetyl-CoA, is a key strategy for achieving commercial success in this organism.

**Results:** Building on YB-392, a *Y. lipolytica* isolate known for stable non-hyphal growth and low citrate production with demonstrated potential for high lipid accumulation, we assembled a heterologous pathway that redirects carbon flux from glucose through the pentose phosphate pathway (PPP) to acetyl-CoA. We used phosphofructokinase (Pfk) deletion to block glycolysis and expressed two non-native enzymes, phosphoketolase (Xpk) and phosphotransacetylase (Pta), to convert PPP-produced xylulose-5-P to acetyl-CoA. Introduction of the pathway in a *pfk* deletion strain that is unable to grow and accumulate lipid from glucose in defined media ensured maximal redirection of carbon flux through Xpk/Pta. Expression of Xpk and Pta restored growth and lipid production from glucose. In 1-L bioreactors, the engineered strains recorded improved lipid yield and cell-specific productivity by up to 19 and 78%, respectively.

**Conclusions:** Yields and cell-specific productivities are important bioprocess parameters for large-scale lipid fermentations. Improving these parameters by engineering the Xpk/Pta pathway is an important step towards developing *Y. lipolytica* as an industrially preferred microbial biocatalyst for lipid production.

**Keywords:** Phosphotransacetylase, Phosphoketolase, Lipid yield, Cell-specific lipid productivity, *Yarrowia lipolytica*, Central carbon metabolism

**Background**

Lipids are important precursors in food, cosmetics, biodiesel and biochemical industries [1]. The ever-increasing demands of these industries are largely fulfilled by plant oil feedstocks [1, 2]. Plantations for oil are dependent on climatic changes, geopolitics and require large arable lands. Oil plantations are continually displacing large areas of tropical forests worldwide, severely affecting their regional biodiversity [2, 3]. These environmental and sustainability concerns have fueled research into microbial oil as an alternative source of lipid production [4, 5].

In recent years, *Yarrowia lipolytica* has emerged as the preferred organism to study and engineer lipid production [6]. It is an oleaginous yeast capable of accumulating
more than 20% of its biomass as lipids [7] and with a few genetic modifications can accumulate over 60% lipid [8–10]. *Y. lipolytica*-derived products have received Generally Regarded As Safe (GRAS) status, and the yeast has a well-developed genetic tool kit for manipulating substrate and product pathways [6]. Lipids in *Y. lipolytica* are mostly stored as triacylglycerol (TAG) molecules (95%), composed mainly of C16 and C18 fatty acids with varying degrees of saturation [11]. Lipid composition alterations to make industrially relevant products like triolein have also been demonstrated in *Y. lipolytica* [12]. Consequently, *Y. lipolytica* is often chosen as a model organism to study the glucose-to-lipid pathway, lipid body biogenesis and homeostasis [4, 13, 14].

De novo fatty acid synthesis requires a constant supply of the metabolic precursor cytosolic acetyl-CoA and the reducing cofactor NADPH (nicotinamide adenine dinucleotide phosphate) [4, 13]. In *Y. lipolytica*, glucose is converted to cytosolic acetyl-CoA through the combined reactions of the glycolytic cycle, mitochondrial pyruvate dehydrogenase (PDH) and ATP:citrate lyase (ACL) (Fig. 1) [7]. The pentose phosphate pathway (PPP) has been shown to supply NADPH for lipid production [15]. The lipid synthesis pathway converts cytosolic acetyl-CoA to C16–18 fatty acyl-CoAs through a series of condensation reactions. Two molecules of NADPH are used for every acetyl unit condensed into a growing C16 fatty acyl chain. Elongating C16 fatty acyl-CoAs to C18 fatty acyl-CoAs also uses two NADPH molecules [16]. While fatty acid desaturation also requires reduced cofactors, it is unclear if the preferred cofactor is NADH or NADPH [16, 17]. Thus, to make one molecule of triolein (C$_{57}$H$_{104}$O$_{6}$) using this biochemical pathway, 27 acetyl-CoA and at least 48 NADPH molecules are needed (Additional file 1: Fig. S1a). To produce the required intermediates, the native lipid pathway utilizes 18 glucose molecules (Additional file 1: Fig. S1a, b). We calculate a theoretical triolein yield from glucose at 0.27 g/g (Eq. 1).

\[
18 \text{ glucose} \rightarrow 27 \text{ Acetyl-CoA} + 48 \text{ NADPH} \rightarrow 1 \text{ C}_{18}:1 \text{ TAG}
\]

Metabolic engineering of the native pathway has improved lipid production in *Y. lipolytica* to nearly the theoretical maximal yield of 0.27 g lipid/g glucose [9, 18–22], when taking into account synthesis of non-lipid yeast biomass. Engineering strategies include overexpressing genes directly implicated in TAG synthesis [8, 19, 23, 24], rerouting glucose flux toward lipid precursor production [18] and deleting genes involved in lipid degradation.
and by-product formation [26]. Combined, these methods maximize flux and productivity through the native pathway to increase lipid production.

Another strategy to improve glucose-to-lipid production involves rewiring central carbon metabolism to improve yield of the biosynthetic lipid precursor acetyl-CoA, the redox cofactor NADPH, or both [22, 27–30]. This increases the theoretical maximum yield of the pathway and usually involves introducing heterologous enzymatic activities and creating new pathways in the organism [27]. One such pathway is the phosphoketolase (PK or Xpk)/phosphotransacetylase (Pta) pathway which has been tested in various organisms including Escherichia coli [31], Saccharomyces cerevisiae [32–35] and Y. lipolytica [28, 30, 36]. Phosphoketolase (Xpk, EC 4.1.2.9, EC 4.1.2.22) converts fructose 6-phosphate (F6P) and/or the PPP intermediate xylulose 5-phosphate (X5P) to acetyl phosphate (AcP) and glyceraldehyde 3-phosphate (Ga3P). Phosphotransacetylase (Pta, EC 2.3.1.8) catalyzes the reversible conversion of AcP to acetyl-CoA. The combined activities of Xpk and Pta produce cytosolic acetyl-CoA from the PPP instead of glycolysis, and thus link it to NADPH production. The Xpk/Pta route towards acetyl-CoA and NADPH is more efficient than Y. lipolytica’s native route via glycolysis and ACL [27] (Additional file 1: Fig. S1c). Overall, the Xpk/Pta pathway (Eq. 2) requires 2.3 fewer moles of glucose to make one mole of triolein compared to the native pathway (comparing Eqs. 1 and 2).

**Xpk/Pta pathway**

\[
15.7 \text{glucose} \rightarrow 27 \text{Acetyl} - \text{CoA} + 48 \text{NADPH} \rightarrow 1 \text{C18 : 1 TAG}
\]

(Eq. 2)

Work in Y. lipolytica has shown that expression of Xpk/Pta can lead to improved lipid phenotypes. Coexpression of Aspergillus nidulans phosphoketolase (AnXPK) and Bacillus subtilis phosphotransacetylase (BsPTA) led to improved yield from glucose [30] and increased lipid content from xylose [36]. Expression of Leuconostoc mesenteroides phosphoketolase (LmXPK) and Clostridium kluyveri phosphotransacetylase (CkPTA) led to higher dry cell weight and lipid content with a moderate increase in lipid yield [28]. Enzymatic activity was not measured, but improved lipid metrics suggested active Xpk/Pta pathways in the engineered strains. These studies were performed in Po1 series strains, derived from a set of backcrosses between the French and American Y. lipolytica wild-type strains W29 and CBS6142-2 [37, 38]. Although well characterized, the Po1 strains exhibit certain traits undesirable for commercial production: auxotrophy, significant citrate production and tendency to grow in the hyphal morphology under certain stresses [37, 39]. Wild-type Y. lipolytica strain YB-392 is a prototroph that has demonstrated potential for very high lipid content while growing entirely in the yeast morphology and with minimal citrate production [21]. It has been established that different Y. lipolytica genetic back-grounds respond differently to genetic engineering, even within the Po1 series [36]. Implementation of an Xpk/Pta pathway in YB-392 therefore remained to be investigated.

In published implementations of the Xpk/Pta pathway in other species, additional engineering was required for successful pathway utilization. In E. coli, 11 gene overexpressions, 9 gene deletions and over 50 genomic mutations accumulated through evolution were engineered to successfully rescue growth in a glycolytic mutant through the Xpk/Pta pathway [31]. In a farnesene-producing S. cerevisiae strain, the aldehyde dehydrogenase genes ALD2 and ALD6 were deleted to make Xpk/Pta the sole source of acetyl-CoA production. Additionally, the glyc-rol-3-phosphate phosphatase gene RHRI2 was deleted as this enzyme exhibited acetyl phosphatase activity and competed with PTA for the substrate AcP [35]. The removal of competing reactions ensures that Xpk/Pta is the only available route for growth and/or acetyl-CoA production.

In this study, we engineered the Xpk/Pta pathway in a glycolysis-deficient pfk Y. lipolytica strain in the YB-392 strain background. Phosphofructokinase (Pfk, EC 2.7.1.11) catalyzes the irreversible production of fructose 1,6-bisphosphate from fructose 6-phosphate (F6P). Carbon flux from glucose to lipids can still move through glycolysis in an otherwise unmodified Xpk/Pta strain, whereas deleting PFK is expected to reroute glucose flux through the PPP [40, 41] and in turn through the Xpk/Pta pathway (Fig. 1). Increased flux through the PPP could result in excess NADPH with negative consequences for growth [42, 43], unless sufficient NADPH-oxidizing reactions are present to restore the redox balance. We hypothesized that introduction of the Xpk/Pta pathway into a pfk-deficient Y. lipolytica strain would correct the NADPH imbalance by providing a route towards the NADPH-oxidizing lipid synthesis pathway (Fig. 1). The Xpk/Pta/Δpfk1 strains engineered in the current study overcame the growth and lipid production deficits of the parent Δpfk1 strain. They also exhibited improved lipid yield and cell-specific lipid productivity over the wild-type. Our work is the first in demonstrating phosphoketolase and phosphotransacetylase enzymatic activities as well as combination of the Xpk/Pta pathway with a PFK deletion in Y. lipolytica, maximizing the effect of the heterologous pathway towards lipid production. YB-392-derived Y. lipolytica strains using the Xpk/Pta/Δpfk1
pathway would be well-suited for industrial applications as increased yield and cell-specific lipid productivity directly tie into better economics for lipid production.

**Results and discussion**

In this study, we chose the wild-type *Y. lipolytica* strain YB-392 as the starting strain for its desirable biocatalyst qualities such as native lipid accumulation levels, minimal citrate formation, non-hyphal morphology and ease of genetic manipulation [10, 39]. This strain has also been used to study and engineer lipid pathway to improve lipid accumulation and alter lipid composition [10, 12].

**Identification of functional heterologous phosphotransacetylase (PTA) and phosphoketolase (XPK) in *Y. lipolytica***

Heterologous PTA and XPK genes from various species of bacteria, archaea, algae and fungi were tested for activity in *Y. lipolytica*. Genes were individually expressed in wild-type strain YB-392 and cell-free extracts were assayed to measure Pta and Xpk activity (lists of all the PTA and XPK genes tested are in Additional file 1: Tables S1.1 and S1.2, respectively). LmXPK, AnXPK, CkPTA and BsPTA were previously expressed in the *Y. lipolytica* Po1 lineage [28, 30, 36]. Xpk and Pta activities were not reported in those studies and, LmXPK and AnXPK did not exhibit activity in our wild-type strain YB-392 (Additional file 1: Table S1.2). The wild-type strain contains no endogenous Xpk or Pta and shows background levels of activity. Strains expressing PTA genes from *Bacillus subtilis* (BsPTA(v1)) and *Thermoanaerobacterium saccharolyticum* and an XPK gene from *Clostridium acetobutylicum* (CaXPK(v1)) exhibited the highest activity in our screens (Figs. 2 and 3). This marks the first published measurement of Pta and Xpk activity in *Y. lipolytica*.

In the course of identifying active genes in *Y. lipolytica*, we found that different methods of screening were successful for PTA and XPK. Linear integrating expression cassettes and codon optimization to *S. cerevisiae* resulted in successful PTA expression. This approach did not yield detectable Xpk activity in our study (data not shown) presumably due to low expression from the candidate genes. Codon optimization of XPK genes to *Y. lipolytica* and expression from replicating plasmids, a method of expression that yields uniform high expression, was required to identify one gene candidate with detectable enzymatic activity (Fig. 3).

**Construction and characterization of the *Y. lipolytica Δpfk1* strain (NS1047)**

To increase glucose flux through the Xpk/Pta pathway, we partially disabled glycolysis by deleting the *PFK1* gene (Fig. 1). *Y. lipolytica* contains only one PFK gene.
and its deletion leads to loss of growth on minimal media with glucose as the only carbon source [44]. We deleted the PFK1 gene in YB-392 to create the Δpfk1 strain NS1047.

Disruption of glycolysis through PFK or PGI deletions can cause growth defects on glucose [40, 42], presumably due to excess NADPH produced by increased glucose flux through the PPP [43, 45]. In organisms that can metabolize cytosolic NADPH, glycolytic-deficient strains retain or regain growth on glucose (e.g., through native cytosolic NADPH oxidase in *Kluyveromyces lactis* [43] or by overexpression of a transhydrogenase enzyme in *E. coli* [45]). *Y. lipolytica* lacks cytosolic NADPH oxidase [46] and homologues to PFK1 [44]. Furthermore, NS1047 was unable to grow in minimal glucose media (Fig. 4a) and lipid production media (Fig. 5b, black bar) with glucose as the primary carbon source. We therefore hypothesize that *Y. lipolytica* cannot tolerate the excess NADPH produced when glucose is consumed in a PFK-deleted strain. Growth on YPD was not abolished, but it was slower for NS1047 than YB-392 (Fig. 4b). The reduced severity of the growth defect on this rich medium could be attributed to the ability of *Y. lipolytica* to utilize amino acids for growth [47] and the ability of a pfk1 deletion mutant to metabolize permissive carbon sources in the presence of glucose [44].

**Engineering the Xpk/Pta pathway into a Δpfk1 strain**

To assemble the Xpk/Pta/Δpfk1 pathway in *Y. lipolytica*, we expressed CaXPK(v1) and BsPTA(v1) in NS1047 (Δpfk1) (Fig. 5). With each transformation step, we screened for the best transformant using appropriate enzymatic assays and measured growth and lipid accumulation on glucose (Additional file 1: Table S2.1). Noticeable Xpk and Pta activities were obtained in the course of constructing strain NS1352 (Fig. 5a). However, NS1352 containing three copies of CaXPK(v1) and two copies of BsPTA(v1), showed minimal improvement in growth or lipid accumulation on glucose when compared to NS1047 (Fig. 5b). One possibility for the lack of improvement is that Xpk and Pta activities were still too low for a functional pathway. As addition of multiple copies of CaXPK(v1) and BsPTA(v1) genes yielded only incremental improvements in enzymatic activities (Fig. 5a), we decided to revisit codon optimization strategies to improve gene expression.

To further improve Xpk and Pta activity in *Y. lipolytica*, different codon optimization strategies were tested on our top performing genes BsPTA, TsPTA and CaXPK. TsPTA codon-optimized to *Y. lipolytica* (GeneArt) exhibited the highest activity and is referred to as TsPTA(v2) from hereon. Improving Xpk activity continued to be challenging and no improvements were observed using the strategies that were successful with Pta (data not shown). Through analysis of publicly available *Y.
lipolytica transcriptomics data (data accessible at NCBI GEO database [48–50]), we noted that the highest expressed genes contained few rare codons (Additional file 1: Fig. S2a). Based on this observation, we manually designed and tested three additional versions of CaXPK (Additional file 1: Fig. S2b). The highest Xpk activity was obtained when all codons present at a frequency $\leq 2\%$ were replaced with their higher frequency counterparts and this gene is referred to as CaXPK(v2).

To determine whether TsPTA(v2) and CaXPK(v2) increase flux through the Xpk/Pta pathway, we tested whether their expression in NS1352 could restore growth and lipid accumulation on glucose. Addition of TsPTA(v2) quadrupled Pta activity (NS1420, Fig. 5a), but growth and lipid production on glucose remained unchanged (Fig. 5b), suggesting that Xpk activity could still be limiting. Consistent with this hypothesis, addition of CaXPK(v2) improved lipid accumulation to near YB-392 levels (NS1457, Fig. 5b, grey bars). Growth on glucose also improved, but was still deficient compared to YB-392 (NS1457, Fig. 5b, black bars). Addition of a second copy of CaXPK(v2) almost quadrupled growth on glucose compared to its parent strain (NS1457 and NS1475, Fig. 5b, black bars). Lipid accumulation remained similar to the parent strain NS1457 and YB-392 (Fig. 5b, grey bars). The observation that lipid accumulation was restored with fewer copies of XPK than were required to restore wild-type growth to a $\Delta pfk1$ strain suggests that more Xpk activity is needed for growth than lipid production.

To further characterize the Xpk/Pta/$\Delta pfk1$ pathway strain NS1475, we carried out batch fermentations in 1-L bioreactors with YB-392 included as control. Two replicate fermentation experiments comparing YB-392 and NS1475 were conducted on two separate occasions to account for any culturing variations. NS1475 was comparable to the wild-type YB-392 in terms of growth and total lipid accumulated (Fig. 6a). NS1475 recorded an improved total lipid yield (+16%), cell-specific lipid productivity (+41%) and lipid content (+16%) over YB-392 (Fig. 6b–d). Our results confirm that the Xpk/Pta pathway can rescue growth and lipid defects of a $\Delta pfk1$ while also improving bioprocess parameters like yield and cell-specific productivity.

---

**Fig. 4 Y. lipolytica growth on glucose.** Strains YB-392 (wild-type) and NS1047 ($\Delta pfk1$) were streaked on A) Yeast Nitrogen Base (YNB) media containing 2% glucose for 4 days, or B) YPD for 2 days as labeled in C.

---

**Confirming improved lipid production with Xpk/Pta/$\Delta pfk1$ genotype**

To confirm that the Xpk/Pta pathway was directly responsible for restoring growth and improving lipid production from glucose in $\Delta pfk1$, we reconstructed the pathway in NS1047 using only TsPTA(v2) and CaXPK(v2) (Fig. 7a). We wanted to eliminate the possibility that the nine rounds of transformation involved in constructing NS1475 resulted in unintentional contributions to the strain's phenotype. As before, Pta and Xpk activity, growth on glucose, and lipid production were monitored at each engineering step (Additional file 1: Table S2.2). One copy of TsPTA(v2) and three copies of CaXPK(v2) were required to restore growth and lipid accumulation to YB-392 levels reducing the number of engineering steps to five instead of nine. Despite the usage of a more active XPK gene sequence, the pathway was again Xpk-limited and required more copies of XPK than PTA to achieve the desired phenotype. Xpk limitation was also reported by Lin et al. while engineering the pathway in *E. coli* [31]. An Xpk bottleneck could be increasingly restricting as we engineer strains toward higher lipid content by combining this pathway with native lipid pathway engineering (e.g., overexpression of DGA1). Additional research could identify a higher-expressing XPK gene that may further reduce the number of engineering steps required to introduce a functional Xpk/Pta/$\Delta pfk1$ pathway in *Y. lipolytica*. 
The two best-performing strains at the end of this engineering strategy (NS1656 and NS1657, Fig. 7a) were further characterized in 1-L batch fermentations alongside YB-392. Under the same fermentation conditions, all three strains attained similar lipid-free biomass (Fig. 7b). As was the case with NS1475, the Xpk/Pta/Δpfk1 strains outperformed YB-392 in lipid yield and cell-specific lipid productivity (Fig. 7c and d). A slight improvement in lipid content was also observed (Fig. 7e). Overall, all three engineered strains showed an improvement in total lipid yield ranging from 13.3%—19.6% and an improvement in cell-specific productivity ranging from 41%—78% over YB-392.

These results confirm that we successfully rewired central carbon metabolism in Y. lipolytica. As expected, redox imbalance created by the PFK deletion led to growth and lipid accumulation defects on glucose media. XPK/PTA expression resulted in confirmed Xpk and Pta activity and corrected this imbalance by providing a route towards the NADPH-oxidizing lipid synthesis pathway, restoring growth and lipid production on glucose. Unlike S. cerevisiae (Meadows et al., 2016), we found that Y. lipolytica did not have any native competing AcP-consuming reactions (no AcP degradation detected in wild-type strain, data not shown). Thus, in engineering the Xpk/Pta pathway in Y. lipolytica we found that Xpk limitation was the main bottleneck and PFK deletion offers a means to ensure maximal pathway utilization.

**Conclusions**

To achieve maximum lipid titer and yield from Y. lipolytica, a combination of native pathway engineering and rewiring of central carbon metabolism may prove to be a successful strategy. In this study, we expressed optimized phosphoketolase and phosphotransacetylase genes in a phosphofructokinase-deficient Δpfk1 strain to demonstrate the use of Xpk/Pta pathway in improving lipid production in the commercially attractive YB-392 strain background. The engineered strains recorded up to 19% higher total lipid yield and up to 78% higher cell-specific productivity compared to the wild-type strain. Such improvements in bioprocess metrics make lipid production in Y. lipolytica more suitable for industrial applications. Since the Xpk/Pta
pathway essentially improves acetyl-CoA production, this pathway can be used to improve bioprocess metrics of other acetyl-CoA derived products including fatty alcohols, sterols, alkenes/alkanes, isoprenoids, etc. [48]. The theoretical improvement in yield makes the Xpk/Pta pathway a compelling technology for large-scale, commodity fermentation in the biofuel and biochemical industries.

Methods

Strains, cultivation and media

Wild-type, haploid *Yarrowia lipolytica* strain YB-392 was obtained from the ARS Culture Collection (NRRL). For routine growth and genetic transformation, strains were cultured in YPD (10 g/L yeast extract, 20 g/L bacto peptone, 20 g/L glucose), YPD/Et/Gly (YPD as described, plus 20 g/L ethanol and 30 g/L glycerol)
and YPG (10 g/L yeast extract, 20 g/L bacto peptone, 20 g/L glycerol) media at 30 °C. 20 g/L agar was added to prepare solid media. Selection was performed using 300 μg/mL hygromycin B (Corning), 500 μg/mL nourseothricin (Werner Bioreagents) or 30 μM 5-fluoro-2'-deoxyuridine (FUDR) (Fisher Scientific).
**PFK1 deletion**

The *Y. lipolytica* PFK1 gene YALI0D16357 was deleted through targeted genomic integration using direct repeats and a combination of positive and negative selection for marker recycling. Using standard molecular biology techniques, a construct was designed comprising the genetic parts listed in Additional file 1: Table S3. A two-fragment deletion cassette was amplified by PCR using a combination of terminal and internal oligonucleotide primers such that the fragments overlapped in the nat marker reading frame, but neither fragment alone contained the entire functional nourseothricin-resistance gene. PCR products were transformed into hydroxyurea-treated cells as described in our previous work [51]. Transformation recovery was in YPD/Et/Gly to provide carbon sources in addition to glucose. Transformed cells were plated on YPD/Et/Gly containing 500 µg/mL nourseothricin. Successful cassette integration replaced the *PFK1* locus by a double recombination event at the 47-bp upstream and 621-bp downstream regions. A longer downstream homology region was chosen to increase the likelihood of this recombination event as opposed to recombination between the homologous 450-bp regions in the integration cassette and upstream of *PFK1*. Nourseothricin-resistant colonies were screened by PCR for the presence of the expected targeted integration product and the absence of the *PFK1* gene. The phenotype of resulting deletion strains was confirmed by plating on defined media with glucose as the only carbon source.

To eliminate the marker cassette, the deletion strains were grown on YPD/Et/Gly agar plates without selection for 1 day to allow for survival of cells that naturally excised the cassette by recombination of the 450-bp direct repeat formed between the endogenous *PFK1* upstream region and the identical sequence introduced in the integration cassette. Subsequent plating of strains on YPD/Et/Gly agar containing 30 µM 5-fluoro-2′-deoxuryridine (FUDR) selected for the absence of the thymidine kinase gene. To identify marker-less *PFK1* deletion strains, FUDR-resistant isolates were screened for reversion to nourseothricin sensitivity and loss of the marker cassette from the *pfk1* locus was confirmed by PCR.

Oligonucleotide primer sequences are included in the Additional file 1: Table S3.1.

**XPK and PTA gene expression**

To identify functional *XPK* and *PTA* genes, expression cassettes were transformed into the desired *Y. lipolytica* strains as a part of a linear integrated expression construct [10] or replicating plasmid composed of the genetic parts listed in Additional file 1: Tables S4.1 and S4.2. For replicating plasmids, 100 ng of undigested plasmid was used in the transformation mix. To assemble the Xpk/Pta/Dpfk1 pathway, NS1047 and subsequent intermediate strains were transformed with linear constructs containing XPK or PTA and positive and negative marker expression cassettes (Additional file 1: Table S4.3). Transformants were selected on antibiotic plates and screened for the highest performance using appropriate enzymatic, lipid and growth assays. Additional file 1: Tables S2.1 and S2.2 describe the screening steps used to construct NS1475 and NS1656-57, respectively. To eliminate the marker cassette in these strains, the chosen isolates were grown on YPD agar plates without selection for one day to allow for survival of cells that naturally excised the cassette by recombination between the identical copies of the *Y. lipolytica* TEF1 promoter driving expression of thymidine kinase and the gene of interest in the integration cassette. Subsequent plating on YPD agar containing 30 µM 5-fluoro-2′-deoxyuridine (FUDR) counter-selects for the thymidine kinase gene. FUDR-resistant isolates were screened by confirmation of reversion to nourseothricin sensitivity to identify marker-less strains.

**Growth and lipid assays**

To evaluate growth on glucose, strains were patched on YNB plates (6.7 g/L Yeast Nitrogen Base without amino acids, 20 g/L agar) or cultured in lipid production media (0.5 g/L urea, 1.5 g/L yeast extract, 0.85 g/L casamino acids, 1.7 g/L Yeast Nitrogen Base without amino acids and ammonium sulfate, 100 g/L glucose, and 5.11 g/L potassium hydrogen phthalate) [10]. Growth in lipid production media was tested by growing strains overnight in YPD, washing with sterile water, and inoculating into the lipid production media at a starting OD<sub>600</sub> optical density measured at 600 nm of 0.05. OD<sub>600</sub> measurements to monitor growth were taken after culturing for 2 days in shake flasks.

To measure lipid accumulation, strains were grown in glycerol (YPG) for 24 h and then switched to a modified Verduyn media [52] (modified to contain no ammonium sulfate and 100 g/L glucose) to induce lipid production. The cells grown in YPG were pelleted, washed with water and resuspended in the modified Verduyn media and cultured for 7 days. These characterizations were carried out in 96-well, 48-well or 24-well deep well plates and 250-mL shake flasks. The lipid Bodipy assay described in our previous work [10] was used with one modification: PBS was used instead of the master mix previously described. Lipid accumulation was measured as fluorescence units normalized to the OD<sub>600</sub> (FI/OD).

**Cell-free extract preparation and enzymatic assays**

Strains were grown in 5 mL YPD or YPG overnight at 30 ºC. The cells were pelleted by centrifugation and after a
wash with autoclaved water, were pelleted again. The pellets were resuspended in lysis buffer Y-PER™ plus (Thermo Scientific) per the manufacturer’s instructions. Protease inhibitor cocktail (Sigma Aldrich) was added (5 µL for every 1 mL of the lysis buffer used) and 0.5-mm glass beads were added at an equal volume to the cell pellet. The cells were homogenized in a FastPrep-24™ 5G (MP biomedicals) (3 cycles of 5.5 m/s for 30 s, with 5 min resting on ice between runs). The homogenized cell lysates were centrifuged at 10,000 rpm for 10 min at 4 °C and the supernatants were stored on ice for immediate use in enzymatic assays. Total protein concentrations were determined by the Pierce™ Coomassie (Bradford) Protein Assay Kit (Thermo Scientific).

Phosphotransacetylase activity was quantified using Ellman’s thiol reagent, 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) which reacts with Coenzyme A to form a mercaptide ion measurable at 412 nm [53], with an extinction coefficient of 13.5 mM−1 cm−1. The 1-mL reaction mixture contained 100 mM Tris–HCl (pH 7.2), 5 mM MgCl₂, 5 mM KH₂PO₄, 0.1 mM DTNB, and 0.1 mM acetyl-CoA [54]. 10–40 µL of cell-free extract was mixed with the assay ingredients, with acetyl-CoA added at the end to start the reaction. Specific activity measurements were calculated.

Phosphoketolase activity was measured using a ferric hydroxamate assay on crude cell-free extracts [55]. The 200 µL reaction mixture contained 0.5 mM thiamine pyrophosphate (TPP), 1 mM DTT, 5 mM MgCl₂, 50 mM morpholine ethane sulfonic acid (MES) buffer (pH 5.5 for all kinetic studies), 333 mM sodium phosphate substrate and 333 mM of either fructose 6-phosphate or ribose 5-phosphate as substrate. Ribose 5-phosphate which is converted to X5P by endogenous enzymes in cell-free extract, was used to measure phosphoketolase activity indirectly [56, 57]. 20–80 µL of cell-free extract was used to initiate the reaction, and the mixture was incubated at 37 °C for 15–30 min. 100 µL of 2 M hydroxylamine hydrochloride (pH 7.0) was added and incubated at room temperature for 10 min to stop the reaction. 600 µL of a 1:1 mixture of 2.5% FeCl₃ in 2 N HCl and 10% trichloroacetic acid was added. The final reaction step results in the formation of the ferric-hydroxamate complex, which was measured spectrophotometrically at 540 nm [58]. For specific activity measurements, reactions were stopped at 5-min intervals and ΔAbs/min was calculated.

Codon optimizations
BsPTA(v1) and TsPTA(v1) genes were codon-optimized to S. cerevisiae using the GeneArt Gene Synthesis service (ThermoFisher Scientific). TsPTA(v2) and CaXPK(v1) were codon-optimized to Y. lipolytica using GeneArt Gene Synthesis service and the open source web application ATGme [59], respectively. CaXPK(v2) was codon-optimized using the ATGme web application by manual replacement of all possible codons in the gene present at a frequency ≤ 2% with their higher frequency counterparts. All the gene sequences used in the strain engineering are listed in Additional file 1: Table S4.

**Glucose batch fermentation in 1-L bioreactors**
Frozen working-stocks of strains were patched onto a YPD plate and grown overnight at 30 °C. A 10-µL loopful of cells was removed from each plate and used to inoculate separate 250-mL baffled Erlenmeyer flasks with 50 mL of lipid production media. Inoculum flasks were cultured overnight at 30 °C with constant agitation of 200 rpm in a New Brunswick I26 incubator shaker, whereupon the OD₆₀₀ was measured. A volume of each flask culture required to initiate its corresponding 1-L bioreactors at a T₀ cell density of 0.4 OD₆₀₀ was transferred to separate sterile conical tubes. Each conical tube was then brought to 50 mL with sterile diH₂O and centrifuged at 4000 rpm for 3 min in an Eppendorf 5810 R centrifuge. The supernatant was decanted and the cells were then resuspended in 50 mL sterile diH₂O. 25 mL of this washed inoculum was used to inoculate each of two 1-L working volume bioreactors (Dasgip, 1.2-L vessels) with medium consisting of: glucose (150 g/L), (NH₄)₂SO₄ (0.5 g/L), KH₂PO₄ (4 g/L), yeast extract (3 g/L), D-biotin (1 mg/L), thiamine hydrochloride (12 mg/L), ZnSO₄·7H₂O (20 mg/L), MnSO₄·H₂O (180 mg/L), CoCl₂·6H₂O (0.03 mg/L), CuSO₄·5H₂O (0.2 mg/L), Na₂MoO₄·2H₂O (160 mg/L), CaCl₂·6H₂O (800 mg/L), FeCl₃·6H₂O (75 mg/L), H₂BO₃ (40 mg/L). Process parameters included a pH control at 3.5 automatically adjusted with 10 N sodium hydroxide, a temperature of 30 °C, aeration at 0.3vvm air, and agitation controlled at 1000 rpm. A sample of 10 mL was taken from each culture once per day. The samples were stored at 4 °C after each harvest until analyzed. For all time-points, broth analysis was conducted via HPLC. Total dry cell weight (DCW) and total lipid content were measured gravimetrically by a two-phase solvent extraction. Cell-specific lipid productivities were calculated once the strains reached lipogenesis and their growth had slowed (day 2–day 5).

**Gravimetric measurement of dry cell weight (DCW)** and total lipid content using a two-phase solvent extraction
Broth volume from each harvested culture sample was added to a separate pre-weighed 2-mL screw-cap microfuge tube (USA Scientific, 1420–8799) to achieve a dried cell mass between 15 and 20 mg. Samples were washed twice with deionized H₂O and centrifuged at...
21,130 × g for 2 min. Pelleted cells were then resuspended in 200 μL of deionized H₂O, frozen at − 80 °C for 30 min, and freeze-dried overnight. Each tube was weighed to obtain the DCW. To each freeze-dried sample and three blank microfuge tubes, 400 mg of glass beads (Sigma, G8772) and 400 μL of a 1:5:1 CPME:MeOH (cyclopentyl methyl ether:methanol) solution was added. Under maximum agitation, samples were then bead-beaten (BioSpec Mini-BeadBeater 8) for 2 min and allowed to cool to room temperature. After having cooled, 640 μL of CPME followed by 640 μL of 10% (w/v) CaCl₂·6H₂O were added to each sample and vortexed. Samples were then centrifuged for 2 min at 21,130 × g, creating two distinct layers. 660 μL (75% of calculated volume) of the top layer, containing CPME and lipid, was transferred to a pre-weighed glass vial. Dispensed samples were evaporated under compressed air until no visual solvent remained and then lyophilized overnight for total solvent removal. The remaining lipid was weighed and corrected by subtracting the average residual mass measured in the blank samples.

HPLC analysis

The extracellular concentrations of glucose, citrate and polyols (erythritol, arabitol and mannitol) were determined by high-performance liquid chromatography analysis. To that end, a 1-mL broth sample was filtered through a 0.2-mm syringe filter and analyzed using an Aminex HPX-87H column (300 mm × 7.8 mm) (Bio-Rad) on an Agilent 1260 Infinity II HPLC equipped with a refraction index detector (Agilent Technologies). The column was eluted with 5 mM H₂SO₄ at a flow rate of 0.6 mL min⁻¹ at 45 °C for 25 min. The eluents were determined by comparing peak retention times to those of known standard substances, and the amounts were quantified by comparing the peak area of the analyte to the peak area of the standard substance at known concentrations.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13068-021-01962-6.

Additional file 1. Additional figures and tables.

Acknowledgements

The authors are grateful to John Sullivan for laboratory support, Hannah Blitzblau and Jean-Marc Nicaud for careful reading of the manuscript, Elena Breznova for scientific advice, Ram Cherukun for critical formatting of the figures and the Novogy team for insightful discussions throughout the course of this work. We also thank Hans Van Dijken for valuable insights into pathway design and for championing our efforts over the years.

Authors’ contributions

AJS and AK designed the pathway. VT performed the PFK deletion. AK screened XPKs and PPTAs, developed enzymatic assays, constructed all the Xpk/ Pta strains in the study and characterized the strains using growth, lipid and enzymatic assays. SC and GC performed all analytical chemistry. AC and KM performed all the fermentation experiments and lipid gravimetric analyses. AK prepared the manuscript with contributions from VT, SC and AC. VT edited and proof-read all the versions of the paper. All authors read and approved the final manuscript.

Funding

This study was wholly funded by Novogy Inc.

Availability of data and materials

All data generated during this study are included in this published article and its Additional file. The publicly available Y. lipolytica transcriptomics data analyzed in this article were accessed from the NCBI GEO database (Series Accession Numbers GSE35445, GSE35446 and GSE35447).

Declarations

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

Not applicable.

Competing interests

AK, ALC, KM, SC, GC and VT are current employees of Ginkgo Bioworks which has a commercial interest in the strains described in this study and is applying for patents on the work described in this study. The authors declare no other non-financial competing interests.

Author details

1 Ginkgo Bioworks, 27 Drydock Ave, Boston, Massachusetts, United States.
2 Belmont, Massachusetts, United States.

Received: 1 September 2020 Accepted: 21 April 2021
Published online: 04 May 2021

References

1. Donot F, Fontana A, Baccou JC, Strub C, Schorr-Galindo S. Single cell oils (SCOs) from oleaginous yeasts and moulds: Production and genetics. Biomass Bioenerg. 2014;68:135–50.
2. Koh JP, Wilcove DS. Is oil palm agriculture really destroying tropical biodiversity? Conserv Lett. 2008;1(2):60–4.
3. Mendes-Oliveira AC, Peres CA, de Maües PCRA, Oliveira GI, Mineiro IGB, de Maria SLS, et al. Oil palm monoculture induces drastic erosion of an Amazonian forest mammal fauna. PLoS ONE. 2017;12(11):e0178650.
4. Beopoulos A, Cescut J, Haddouche R, Unibaletra JL, Molina-Jouve C, Nicaud JM. Yarrowia lipolytica as a model for bio-oil production. Prog Lipid Res. 2009;48(6):375–87.
5. Pinot S, Pilaradorado M. —Feedstocks for advanced biodiesel production. In: Luque R, Melero JA, editors. Advances in biodiesel production. Elsevier: Woodhead Publishing; 2012. p. 69–90.
6. Nicaud JM. Yarrowia lipolytica. Yeast. 2012;29(10):409–18.
7. Ratledge C, Wynn JP. The biochemistry and molecular biology of lipid accumulation in oleaginous microorganisms. Adv Appl Microbiol. 2002;51:1–51.
8. Tai M, Stephanopoulos G. Engineering the push and pull of lipid biosynthesis in oleaginous yeast Yarrowia lipolytica for biofuel production. Metab Eng. 2013;15:1–9.
9. Blazeck J, Hill A, Liu L, Knight R, Miller J, Pan A, et al. Harnessing Yarrowia lipolytica lipogenesis to create a platform for lipid and biofuel production. Nat Commun. 2014. https://doi.org/10.1038/ncomms4131.
50. Ochoa-Estopier A, Bouscaut J, Morin N, Trouilh L, Le Berre V, Loux V, et al. Metab Eng. 2014;28(2):129–40.
51. van Rossum HM, Kozak BJ, Pronk JT, van Maris AJA. Engineering cytosolic acetyl-coenzyme A supply in Saccharomyces cerevisiae: Pathway stoichiometry, free-energy conservation and redox-cofactor balancing. Metab Eng. 2016;36:99–115.
52. Qiao K, Wasylenko TM, Zhou K, Xu P, Stephanopoulos G. Lipid production in Yarrowia lipolytica is maximized by engineering cytosolic redox metabolism. Nat Biotechnol. 2017;35(3):230–7.
53. Ku JT, Chen AT, Lan EL. Metabolic engineering design strategies for increasing acetyl-CoA flux. Metabolites. 2020;10(4):166.
54. Xu P, Qiao K, Ahn WS, Stephanopoulos G. Engineering Yarrowia lipolytica as a platform for synthesis of drop-in transportation fuels and oleochemicals. Proc Natl Acad Sci USA. 2016;113(39):10848–53.
55. Lin PP, Langer AL, Wu TY, Xu SC, Lee AS, Gao F, et al. Construction and evolution of an Escherichia coli strain relying on nonoxidative glycolysis for sugar catabolism. Proc Natl Acad Sci USA. 2018;115(14):3533–46.
56. Sonderegger M, Schümerli M, Sauer U. Metabolic engineering of a phosophokeytaser pathway for pentose catabolism in Saccharomyces cerevisiae. Appl Environ Microbiol. 2004;70(5):2892–7.
57. Kochan K, Sievers V, Nielsen J. Improved polyhydroxybutyrate production by Saccharomyces cerevisiae through the use of the phosphoketolase pathway. Biotechnol Bioeng. 2013;110(8):2216–24.
58. de Jong BW, Shi V, Sievers V, Nielsen J. Improved production of fatty acid ethyl esters in Saccharomyces cerevisiae through up-regulation of the ethanol degradation pathway and expression of the heterologous phosphoketolase pathway. Microb Cell Fact. 2014;13(1):39.
59. Metados AL, Hawkins KM, Tsegaye Y, Antipov E, Kim Y, Raetz L, et al. Rewriting yeast central carbon metabolism for industrial isoprenoid production. Nature. 2016;537(7622):694–7.
60. Niehus X, Crutz-Le Coq A-M, Sandoval G, Nicola J-M, Ledesma-Amaro R. Engineering Yarrowia lipolytica to enhance lipid production from lignocellulosic materials. Biotechnol Biofuels. 2018. https://doi.org/10.1186/s13068-018-1010-6.
61. Madzak C, Tréton B, Blanchin-Roland S. Strong hybrid promoters and integrative expression/secretion vectors for quasi-constitutive expression of heterologous proteins in the yeast Yarrowia lipolytica. J Mol Microbiol Biotechnol. 2020;2(2):207–16.
51. Tsakraklides V, Brevnova E, Stephanopoulos G, Shaw AJ. Improved gene targeting through cell cycle synchronization. Galli A, editor. PLoS ONE. 2013;10(7):e0133434.

52. Verduyn C, Postma E, Scheffers WA, Van Dijken JP. Effect of benzoic acid on metabolic fluxes in yeasts: a continuous-culture study on the regulation of respiration and alcoholic fermentation. Yeast. 1992;8(7):501–17.

53. Stere PA, Brazil H, Gonen L. The citrate condensing enzyme of pigeon breast muscle and moth flight muscle. Acta chem scand. 1963;17(Suppl 1):129–34.

54. Bock AK, Glasemacher J, Schmidt R, Schönheit P. Purification and characterization of two extremely thermostable enzymes, phosphate acetate transferase and acetate kinase, from the hyperthermophilic eubacterium Thermotoga maritima. J Bacteriol. 1999;181(6):1861–7.

55. Lipmann FA, Tuttle LC. A specific micromethod for the determination of acyl phosphates. J Biol Chem. 1945. https://doi.org/10.1016/S0021-9258(19)51298-4.

56. Bogorad IW, Lin T-S, Liao JC. Synthetic non-oxidative glycolysis enables complete carbon conservation. Nature. 2013;502(7473):693–7.

57. Bergman A, Siewers V, Nielsen J, Chen Y. Functional expression and evaluation of heterologous phosphoketolases in Saccharomyces cerevisiae. AMB Express. 2016;6(1):115.

58. Glenn K, Ingram-Smith C, Smith KS. Biochemical and kinetic characterization of xylulose 5-phosphate/fructose 6-phosphate phosphoketolase 2 (Xfp2) from Cryptococcus neoformans. Eukaryot Cell. 2014;13(5):657–63.

59. Daniel E, Onwukwe GU, Wierenga RK, Quaggin SE, Vainio SJ, Krause M. ATGme: Open-source web application for rare codon identification and custom DNA sequence optimization. BMC Bioinformatics. 2015. https://doi.org/10.1186/s12859-015-0743-5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.